{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:11:17Z","timestamp":1792275077480,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["1SC2GM130478"],"award-info":[{"award-number":["1SC2GM130478"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010937","name":"St. John's University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115754","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T01:54:25Z","timestamp":1697853265000},"page":"115754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma"],"prefix":"10.1016","volume":"168","author":[{"given":"Aishwarya","family":"Saraswat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Vartak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehab","family":"Hegazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trishaal Janardhanam Raghavendra","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blase","family":"Billack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115754_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.biopha.2023.115754_bib2","article-title":"Cancer statistics, 2023","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.115754_bib3","article-title":"Metastatic melanoma - A review of current and future drugs","volume":"2012","author":"Velho","year":"2012","journal-title":"Drugs Context"},{"issue":"6","key":"10.1016\/j.biopha.2023.115754_bib4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"15_suppl","key":"10.1016\/j.biopha.2023.115754_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.9091","article-title":"Targeting BET proteins in melanoma: a novel treatment approach","volume":"31","author":"Paoluzzi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2023.115754_bib6","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/j.celrep.2017.11.022","article-title":"Melanoma therapeutic strategies that select against resistance by exploiting MYC-Driven evolutionary convergence","volume":"21","author":"Singleton","year":"2017","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115754_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2023.115754_bib8","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","article-title":"Nanoformulation of PROteolysis targeting chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer","volume":"15","author":"Saraswat","year":"2020","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115754_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08702","article-title":"Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy","volume":"8","author":"Saraswat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2023.115754_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-022-03184-3","article-title":"Susceptibility of lung carcinoma cells to nanostructured lipid carrier of ARV-825, a BRD4 degrading proteolysis targeting chimera","author":"Vartak","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2023.115754_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105039","article-title":"BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: preformulation studies formulation development and in vitro evaluation","volume":"138","author":"Rathod","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.115754_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103387","article-title":"Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)","volume":"28","author":"Saraswat","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.biopha.2023.115754_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/jcph.277","article-title":"Vemurafenib oral bioavailability: an insoluble problem","volume":"54","author":"Szmulewitz","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115754_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2023.115754_bib15","article-title":"Development and optimization of stealth liposomal system for enhanced in vitro cytotoxic effect of quercetin","volume":"55","author":"Saraswat","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"14","key":"10.1016\/j.biopha.2023.115754_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","article-title":"Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro","volume":"16","author":"Vartak","year":"2021","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.biopha.2023.115754_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071005","article-title":"Development of dual ARV-825 and Nintedanib-Loaded PEGylated nano-liposomes for synergistic efficacy in vemurafnib-resistant melanoma","volume":"13","author":"Fu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2023.115754_bib18","article-title":"Evaluation of the antifungal activity of an ebselen-loaded nanoemulsion in a mouse model of vulvovaginal candidiasis","volume":"37","author":"Menon","year":"2021","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115754_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010113","article-title":"Characterization of melanoma cell lines resistant to vemurafenib and evaluation of their responsiveness to EGFR- and MET-inhibitor treatment","volume":"21","author":"Dratkiewicz","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.115754_bib20","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.drudis.2021.11.015","article-title":"Stromal disruption facilitating invasion of a 'nano-arsenal' into the solid tumor","volume":"27","author":"Fu","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2023.115754_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.phrs.2016.07.017","article-title":"Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation","volume":"111","author":"Sandri","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2023.115754_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119494","article-title":"Hydrophobic ion pair loaded self-emulsifying drug delivery system (SEDDS): a novel oral drug delivery approach of cromolyn sodium for management of bronchial asthma","volume":"585","author":"Asfour","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2023.115754_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejpb.2020.04.025","article-title":"Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery","volume":"152","author":"Ismail","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2023.115754_bib24","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2147\/IJN.S167958","article-title":"Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect","volume":"13","author":"Pangeni","year":"2018","journal-title":"Int. J. Nanomed."},{"issue":"41","key":"10.1016\/j.biopha.2023.115754_bib25","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1039\/C9TB01081E","article-title":"Biomaterial-tight junction interaction and potential impacts","volume":"7","author":"Han","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"2","key":"10.1016\/j.biopha.2023.115754_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11020058","article-title":"Improved dissolution and oral bioavailability of valsartan using a solidified supersaturable self-microemulsifying drug delivery system containing gelucire((R)) 44\/14","volume":"11","author":"Shin","year":"2019","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.biopha.2023.115754_bib27","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1080\/10717544.2016.1214990","article-title":"Controversies with self-emulsifying drug delivery system from pharmacokinetic point of view","volume":"23","author":"Chatterjee","year":"2016","journal-title":"Drug Deliv."},{"issue":"28","key":"10.1016\/j.biopha.2023.115754_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000161","article-title":"Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report","volume":"93","author":"Orouji","year":"2014","journal-title":"Medicine"},{"issue":"3","key":"10.1016\/j.biopha.2023.115754_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"DeCog, Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115754_bib30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/jcmm.14755","article-title":"Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib","volume":"24","author":"Atzori","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.biopha.2023.115754_bib31","first-page":"5151","article-title":"Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenibresistant melanoma cell lines","volume":"18","author":"Takahashi","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.115754_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112275","article-title":"Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma","volume":"396","author":"Fu","year":"2020","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2023.115754_bib33","doi-asserted-by":"crossref","first-page":"23770","DOI":"10.1038\/srep23770","article-title":"BET bromodomain suppression inhibits vegf-induced angiogenesis and vascular permeability by blocking VEGFR2-mediated activation of PAK1 and eNOS","volume":"6","author":"Huang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115754_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3389\/fphar.2020.01043","article-title":"A bromodomain-containing protein 4 (BRD4) inhibitor suppresses angiogenesis by regulating AP-1 expression","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharm."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223015524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:42:40Z","timestamp":1779918160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223015524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":34,"alternative-id":["S0753332223015524"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115754","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115754"}}